acute ischemic stroke
Conditions
Interventions
Experimental group:Liraglutide plus Liraglutide
control group:Standard hypoglycemic therapy
Sponsors
Shanghai 6th People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years old; 2. Patients with acute ischemic stroke diagnosed by CT / MRI within 12 hours after onset; if the onset time of stroke is not clear, it shall be calculated according to the last time when the patient appears to be normal; 3. blood glucose: >=6.1mmol/L at random; 4. The baseline NIHSS score was 3-22 (exercise score >=2); 5. Mrs score was 0-1 before stroke; 6. Sign informed consent.
Exclusion criteria
Exclusion criteria: 1. History of type 1 diabetes mellitus; 2. Those who are using liraglutide or linagliptin; 3. Contraindications of MRI (metal implantation, claustrophobia, unclear consciousness, difficult to cooperate with); 4. Other stroke clinical trial drugs were used; 5. Severe neuropsychiatric disorders that should affect the evaluation of clinical outcomes; 6. The survival time of patients with other serious diseases was less than 90 days; 7. Pregnant women or lactation period; 8. Previous history of allergy or intolerance to liraglutide or linagliptin; 9. There are contraindications for drug use; 10. Reject the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Rankin Scale score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of incidence and fluctuation of hypoglycemia;14d NIHSS score;Changes in cognitive function scores;The progressive enlargement and percentage of infarct volume and ischemic penumbra volume showed on MRI at 14 days;Changes of inflammatory immune indexes and metabonomics; | — |
Countries
China
Contacts
Public ContactYuwu Zhao
Shanghai 6th People's Hospital
Outcome results
None listed